Pharmacologic management of agitation in Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 17, Issue 1-2, 2004, Pages 65-77

  Profenno, Louis A ^a   Tariot, Pierre N ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Agitation; Alzheimer's disease; Anticonvulsant; Antipsychotic; Cholinesterase inhibitor; Dementia; Psychopharmacology

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CITALOPRAM; CLOZAPINE; FLUOXETINE; FLURAZEPAM; FLUVOXAMINE; HALOPERIDOL; LORAZEPAM; METRIFONATE; NEUROLEPTIC AGENT; NITRAZEPAM; OLANZAPINE; OXAZEPAM; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TIAPRIDE; TRAZODONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

AGGRESSION; AGITATION; AKATHISIA; ANTEROGRADE AMNESIA; ATAXIA; BLOOD TOXICITY; BONE MARROW TOXICITY; CAREGIVER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DELIRIUM; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EMOTIONAL DISORDER; ENVIRONMENTAL FACTOR; EXTRAPYRAMIDAL SYMPTOM; FALLING; GASTROINTESTINAL SYMPTOM; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPONATREMIA; INSOMNIA; LIVER DYSFUNCTION; MORBIDITY; NURSING HOME; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RASH; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL ASPECT; SOMNOLENCE; STROKE; TARDIVE DYSKINESIA; TRANSIENT ISCHEMIC ATTACK; URINARY TRACT INFECTION; VERTIGO; WITHDRAWAL SYNDROME;

AGED; ALZHEIMER DISEASE; ANTICONVULSANTS; CHOLINESTERASE INHIBITORS; HUMANS; PSYCHOMOTOR AGITATION;

EID: 0344629364     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074278     Document Type: Review

References (108)

1. Tariot P, Blazina L: The psychopathology of dementia; in Morris J (ed): Handbook of Dementing Illnesses. New York, Marcel Dekker, 1993, pp 461-475.
2. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC: Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157:708-714.
3. Paulsen JS, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, et al: Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimer's disease. Neurology, in press.
4. Cohen-Mansfield J, Werner P: Longitudinal changes in behavioral problems in old age: A study in an adult day care population. J Gerontol A Biol Sci Med Sci 1998;53:M65-M71.
5. Aarsland D, Cummings JL, Yenner G, Miller B: Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Am J Psychiatry 1996; 153:243-247.
6. Deutsch LH, Bylsma FW, Rovner BW, Steele C, Folstein MF: Psychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry 1991;148:1159-1163.
7. Gilley DW, Wilson RS, Beckett LA, Evans DA: Psychotic symptoms and physically aggressive behavior in Alzheimer's disease. J Am Geriatr Soc 1997;45:1074-1079.
8. Tractenberg RE, Weiner MF, Thal LJ: Estimating the prevalence of agitation in community-dwelling persons with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2002;14:11-18.
9. Cohen-Mansfield J, Billig N: Agitated behaviors in the elderly. 1. A conceptual review. J Am Geriatr Soc 1986;34:711-721.
10. Tariot PN: Treatment of agitation in dementia. J Clin Psychiatry 1999;60(suppl 8):11-20.
11. Loy R, Tariot PN, Rosenquist K: Alzheimer's disease: Behavioral management; in Katz IR, Oslin D, Lawton MP (eds): Annual Review of Gerontology and Geriatrics: Focus on Psychopharmacologic Interventions in Late Life. New York, Springer, 1999, pp 136-194.
12. Rosenquist K, Tariot PN, Loy R: Treatments for behavioral and psychological symptoms in Alzheimer's disease and other dementias; in Ames D, Burns A, O'Brien J (eds): Dementia. London, Chapman and Hall, 2000.
13. Smith M, Buckwalter K, Mitchell S: Geriatric Mental Health Training Series. New York City, Springer, 1993.
14. Gwyther L, Rabins P: Practical approaches for treating behavioral symptoms of people with mild to moderate Alzheimer's disease. Primary Psychiatry 1996;3:27-37.
15. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP: Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology (Berl) 2001;155:128-134.
16. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP: Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-18.
17. Brook S, Lucey JV, Gunn KP: Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone IM Study Group. J Clin Psychiatry 2000;61:933-941.
18. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, Feldman PD, Mintzer JE, Beckett LM, Breier A: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26;:494-504.
19. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P: A double-blind, placebo-controlled dose-response comparison of intramuscular olanza-pine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-448.
20. Rabins P, Blacker D, Bland W, Bright-Long L, Cohen E, Katz I, Rovner B, Schneider L, American Psychiatric Association Work Group on Alzheimer's Disease and Related Dementias: Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154:1-39.
21. Alexopoulos GS, Silver JM, Kahn DA, Frances A, Carpenter D: Treatment of Agitation in Older Persons with Dementia. A Postgraduate Medicine Special Report. New York, NY, McGraw-Hill, 1998, pp 1-88.
22. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL: Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the Ameri-can Academy of Neurology. Neurology 2001; 56:1154-1166.
23. Leibovici A, Tariot PN: Agitation associated with dementia: A systematic approach to treatment. Psychopharmacol Bull 1988;24:49-53.
24. Devanand DP: Depression in dementia; in Qizilbash N, Schneider L, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T (eds): Evidence-Based Dementia: A Practical Guide to Diagnosis and Management. Oxford, Blackwell Science Ltd, 2000.
25. Tariot PN, Schneider L, Mintzer J, et al: Safety and tolerability of divalproex sodium for the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial. Curr Ther Res 2001;62:51-67.
26. Tariot P, Schneider L, Katz I, Mintzer J, Street J: Quetiapine in nursing home residents with Alzheimer's dementia and psychosis. Am J Geriatr Psychiatry 2002;10:93.
27. De Deyn PP, Jeste DV, Auby P, Carson W, Marcus R, Kujaawa M, McQuade RD, Schneider LS, Mintzer J: Aripiprazole in dementia of the Alzheimer's type. 16th Annu Meet Am Assoc Geriatr Psychiatry, Honolulu, Hawaii, March 2003.
28. Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, Brandt J, Rabins PV: Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the Depression in Alzheimer's Disease Study. Am J Psychiatry 2000;157:1686-1689.
29. Tariot PN, Ryan JM, Porsteinsson AP, Loy R, Schneider LS: Pharmacologic therapy for behavioral symptoms of Alzheimer's disease. Clin Geriatr Med 2001;17:359-376.
30. Schneider LS, Pollock VE, Lyness SA: A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38: 553-563.
31. Lanctot KL, Best TS, Mittmann N, Liu BA, Oh PI, Einarson TR, Naranjo CA: Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998;59:550-561.
32. Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A, Fell RL, McAdams LA: Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52:756-765.
33. Devanand DP, Marder K, Michaels K, Sackeim HA, Bell K, Sullivan M, Cooper T, Pelton GH, Mayeux R: A randomized, placebo-controlled, dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998;155: 1512-1520.
34. Helmes E: Multidimensional Observation Scale for Elderly Subjects (MOSES). Psychopharmacol Bull 1988;24:733-745.
35. Allain H, Dautzenberg PH, Maurer K, Schuck S, Bonhomme D, Gerard D: Double-blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl) 2000;148:361-366.
36. Ballard C, Grace J, McKeith I, Holmes C: Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998;351: 1032-1033.
37. The Parkinson Study Group: Low-dose cloza-pine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340:757-763.
38. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M: Comparison of risperi-done and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60:107-115.
39. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PLJ, Eriksson S, Lawlor BA: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of demetia. Neurology 1999;53:946-955.
40. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-143.
41. Cohen-Mansfield J: Agitated behaviors in the elderly. 2. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc 1986;34:722-727.
42. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, National Institute of Mental Health, 1976.
43. Wooltorton E. Risperidone (Risperdal): Increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269-1270.
44. Schneider L, Dagerman K: Metaanalysis of atypical antipsychotics for dementia patients: Balancing efficacy and adverse events (abstract II-69, NCDEU 43rd Annu Meet 5/27-30), unpublished. www.nimh.nih.gov./ncdeu/index.cfm.
45. Satterlee WG, Reams SG, Burns PR, Hamilton S, Tran PV, Tollefson GD: A clinical update in olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients (abstract). Psychopharmacol Bull 1995;31:534.
46. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000;57:968-976.
47. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gorbein J: The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
48. Wood S, Cummings JL, Hsu MA, Barclay T, Wheatley MV, Yarema KT, Schnelle JF: The use of the neuropsychiatric inventory in nursing home residents: Characterization and measurement. Am J Geriatr Psychiatry 2000;8:75-83.
49. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
50. Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, Breier A: Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 2001;16(suppl 1):S62-S70.
51. Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW: Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000;22:1068-1084.
52. Parsa MA, Bastani B: Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998;10:216-219.
53. Rosen WG, Mohs R, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
54. Scharre DW, Chang SI: Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 2002;16: 128-130.
55. Davis P, Baskys A: Quetiapine effectively reduces psychotic symptoms in patients with Lewy body dementia: An advantage of the unique pharmacological profile? Brain Aging 2002;2:49-53.
56. Jeste DV, Finkel SI: Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000;8:29-34.
57. Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenheck RA, Small GW, Lebowitz B, Lieberman JA: National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry 2001;9:346-360.
58. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA: Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150-1155.
59. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP: Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-719.
60. Coccaro EF, Kramer E, Zemishlany Z, Thorne A, Rice CM, Giordani B, Duvvi K, Patel BM, Torres J, Nora R: Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990; 147:1640-1645.
61. Christensen DB, Benfield WR: Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. J Am Geriatr Soc 1998;46:620-625.
62. Patel S, Tariot PN: Use of benzodiazepines in behaviorally disturbed patients: Risk-benefit ratio; in Lawler BA (ed): Behavioral Complications of Alzheimer's Disease. Washington, American Psychiatric Association Press, 1995, pp 153-170.
63. Levy MA, Burgio LD, Sweet R, Bonino P, Janosky J, Perel J: A trial of buspirone for the control of disruptive behaviors in community-dwelling patients with dementia. Int J Geriatr Psychiatry 1994;9:841-848.
64. Lawlor BA: A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease. Int J Geriatr Psychiatry 1994;9:55-59.
65. Cantillon M, Brunswick R, Molina D, Bahro M: Buspirone vs haloperidol: A double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriatr Psychiatry 1996;4:263-267.
66. Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME: A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997;5:60-69.
67. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ: Treatment of agitation in AD: A randomized, placebo-controlled clinical trial. Neurology 2000;55:1271-1278.
68. Nyth AL, Gottfries CG: The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multi-centre study. Br J Psychiatry 1990;157:894-901.
69. Ragneskog H, Eriksson S, Karlsson I, Gottfries CG: Long-term treatment of elderly individuals with emotional disturbances: An open study with citalopram. Int Psychogeriatr 1996;8: 659-668.
70. Pollock BG, Mulsant BH, Sweet R, Burgio LD, Kirshner MA, Shuster K, Rosen J: An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. Am J Geriatr Psychiatry 1997;5:70-78.
71. Levin HS, High WM, Goethe KE, Sisson RA, Overall JE, Rhoades HM, Eisenberg HM, Kalisky Z, Gary HE: The Neurobehavioral Rating Scale: Assessment of the behavioural sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry 1987;50:183-193.
72. Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, Marin R, Jacob NJ, Huber KA, Kastango KB, Chew ML: Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002;159:460-465.
73. Ramadan FH, Naughton BJ, Bassanelli AG: Treatment of verbal agitation with a selective serotonin reuptake inhibitor. J Geriatr Psychiatry Neurol 2000;13:56-59.
74. Coccaro EF: Neurotransmitter correlates of impulsive aggression in humans. Ann NY Acad Sci 1996;794:82-89.
75. Chambers CA, Bain J, Rosbottom R, Ballinger BR, McLaren S: Carbamazepine in senile dementia and overactivity - A placebo-controlled double-blind trial. IRCS Med Sci 1982;10: 505-506.
76. Tariot PN, Erb R, Leibovici A, Podgorski CA, Cox C, Asnis J, Kolassa J, Irvine C: Carbamazepine treatment of agitation in nursing home patients with dementia: A preliminary study. J Am Geriatr Soc 1994;42:1160-1166.
77. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C: Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155:54-61.
78. Tariot PN, Frederiksen K, Erb R, Leibovici A, Podgorski, CA, Asnis J, Cox C: Lack of carbamazepine toxicity in frail nursing home patients: A controlled study. J Am Geriatr Soc 1995;43:1026-1029.
79. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': A practical method for grading the cognitive state of patients by the clinician. J Psychiatr Res 1975;12:189-198.
80. Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS: A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer's disease. Am J Geriatr Psychiatry 2001;9:400-405.
81. Tariot PN: Valproate use in neuropsychiatric disorders in the elderly. Psychopharmacol Bull, submitted.
82. Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, Noviasky J, Kowalski N, Holt CJ, Irvine C: Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001;9:58-66.
83. Porsteinsson AP, Tariot PN, Jakimovich LJ, et al: Valproate therapy for agitation in dementia: Open-label extension of a double-blind trial. Am J Geratr Psychiatry2003;11:434-440.
84. Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P: Sodium valproate in the treatment of aggressive behavior in patients with dementia - A randomized placebo-controlled clinical trial. Int J Geriatr Psychiatry 2002;17:579-585.
85. Regan WM, Gordon SM: Gabapentin for behavioral agitation in Alzheimer's disease. J Clin Psychopharmacol 1997;17:59-60.
86. Herrmann N, Lanctot K, Myszak M: Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol 2000;20:90-93.
87. Hawkins JW, Tinklenberg JR, Sheikh JI, Peyser CE, Yesavage JA: A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. Am J Geriatr Psychiatry 2000;8: 221-225.
88. Roane DM, Feinberg TE, Meckler L, Miner CR, Scicutella A, Rosenthal RN: Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry Clin Neurosci 2000;12:40-43.
89. Megna JL, Devitt PJ, Sauro MD, Dewan MJ: Gabapentin's effect on agitation in severely and persistently mentally ill patients. Ann Pharmacother 2002;36:12-16.
90. Manji HK, Moore GJ, Chen G: Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: A role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 2000;61(suppl 9):82-96.
91. Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S: Mood stabilizers in Alzheimer's disease: Symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 2002;54:1567-1577.
92. Cummings JL: Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 2000;157:4-16.
93. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230.
94. Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI: The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. J Clin Psychiatry 1999;60:318-325.
95. Cummings JL, et al: Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease. J Geriatr Psychiatry Neurol 2001;14:101-108.
96. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfled S, Ding C, Galantamine USA-10 Study Group: A 5-month, randomized placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276.
97. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-1599.
98. Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y: Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol 2002;25: 313-317.
99. Winblad B, Mobius HJ, Stoffler A: Glutamate receptors as a target for Alzheimer's disease - Are clinical results supporting the hope? J Neural Transm Suppl 2002;62:217-225.
100. van der Kam P, Mol F, Wimmers MFHC: Beoordelingsschaal voor oudere patienten (BOP). Deventer, Van Loghum Slaterus, 1971.
101. Winblad B, Poritis N: Memantine in severe dementia: Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146.
102. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, for the Memantine Study Group: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
103. Tariot PN, Schneider LS, Katz IR: Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. J Geriatr Psychiatry Neurol 1995;8(suppl 1):S28-S39.
104. Shankle WR, Nielson KA, Cotman CW: Low-dose propranolol reduces aggression and agitation resembling that associated with orbito-frontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 1995;9: 233-237.
105. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, Gracon S: Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality, Tacrine Study Group. Neurology 1996;47:166-177.
106. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST: Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-314.
107. 2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 1995;16:187-198.
108. Loy R, Tariot PN: Neuroprotective properties of valproate: Potential benefit for AD and tauopathies. J Mol Neurosci 2002;19:303-307.